

Study Quality

(A) RCT studies




Figure 1: Cochrane Risk of Bias Assessment of Randomised Controlled Trials included in the Analysis

(B) Non-RCT studies

The quality of non-RCT studies was assessed using the Newcastle-Ottawa-Scale :

Trial name	selection	outcome	Agreed total stars / 6
Avet-Loiseau et al. [1]	**	***	5
Chang et al. [2]	*	***	4
Fukushima et al. [3]	*	***	4
Hou et al. [4]	**	***	5
Kneppers et al. [5]	**	***	5
Lacy et al. [6]	**	***	5
Moore et al. [7]	*	***	4
Oehrlein et al. [8]	**	***	5
Pantani et al. [9]	*	***	4
Richardson et al. [10]	**	***	5
Terpos et al. [11]	**	***	5
Walter-Croneck et al. [12]	**	***	5

1. Avet-Loiseau, H., et al., *Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone*. *Leukemia*, 2010. **24**(3): p. 623.
2. Chang, H., et al., *Bortezomib therapy response is independent of cytogenetic abnormalities in relapsed/refractory multiple myeloma*. *Leukemia research*, 2007. **31**(6): p. 779-782.
3. Fukushima, T., et al., *Efficacy and safety of bortezomib plus dexamethasone therapy for refractory or relapsed multiple myeloma: once-weekly administration of bortezomib may reduce the incidence of gastrointestinal adverse events*. *Anticancer research*, 2011. **31**(6): p. 2297-2302.
4. Hou, J., et al., *A multicenter, open-label, phase 2 study of lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: the MM-021 trial*. *Journal of hematology & oncology*, 2013. **6**(1): p. 1.
5. Kneppers, E., et al., *Analysis of efficacy and prognostic factors of lenalidomide treatment as part of a Dutch compassionate use program*. *Clinical Lymphoma Myeloma and Leukemia*, 2010. **10**(2): p. 138-143.
6. Lacy, M., et al., *Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM)*. *Leukemia*, 2010. **24**(11): p. 1934-1939.
7. Moore, S., et al., *Weekly intravenous bortezomib is effective and well tolerated in relapsed/refractory myeloma*. *European journal of haematology*, 2013. **90**(5): p. 420-425.
8. Oehrlein, K., et al., *Successful treatment of patients with multiple myeloma and impaired renal function with lenalidomide: results of 4 German centers*. *Clinical Lymphoma Myeloma and Leukemia*, 2012. **12**(3): p. 191-196.
9. Pantani, L., et al., *Bortezomib and dexamethasone as salvage therapy in patients with relapsed/refractory multiple myeloma: analysis of long-term clinical outcomes*. *Annals of hematology*, 2014. **93**(1): p. 123-128.
10. Richardson, P.G., et al., *PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma*. *Blood*, 2013. **122**(14): p. 2331-2337.
11. Terpos, E., et al., *The combination of intermediate doses of thalidomide with dexamethasone is an effective treatment for patients with refractory/relapsed multiple myeloma and normalizes abnormal bone remodeling, through the reduction of sRANKL/osteoprotegerin ratio*. *Leukemia*, 2005. **19**(11): p. 1969-1976.
12. Walter-Croneck, A., et al., *Case-adjusted bortezomib-based strategy in routine therapy of relapsed/refractory multiple myeloma shown to be highly effective—A report by Polish Myeloma Study Group*. *Leukemia research*, 2014. **38**(7): p. 788-794.